Point72 Asia Singapore Pte. Ltd. Takes Position in Agenus Inc. (NASDAQ:AGEN)

Point72 Asia Singapore Pte. Ltd. bought a new position in Agenus Inc. (NASDAQ:AGEN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 6,343 shares of the biotechnology company’s stock, valued at approximately $106,000.

A number of other hedge funds have also made changes to their positions in AGEN. Vanguard Group Inc. grew its stake in Agenus by 13.7% during the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after buying an additional 4,134,232 shares during the last quarter. Key Client Fiduciary Advisors LLC grew its position in Agenus by 38.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 858,969 shares of the biotechnology company’s stock worth $498,000 after acquiring an additional 236,500 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Agenus by 1,959.9% during the 1st quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after purchasing an additional 720,629 shares in the last quarter. Crestline Management LP raised its position in Agenus by 6.5% in the 4th quarter. Crestline Management LP now owns 708,480 shares of the biotechnology company’s stock valued at $587,000 after purchasing an additional 43,480 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in Agenus by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 13,604 shares in the last quarter. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Price Performance

Shares of NASDAQ:AGEN opened at $5.31 on Friday. The stock has a market cap of $111.50 million, a price-to-earnings ratio of -0.41 and a beta of 1.36. The company has a 50 day moving average of $5.53 and a 200-day moving average of $9.99. Agenus Inc. has a one year low of $4.41 and a one year high of $23.40.

Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The business had revenue of $23.51 million for the quarter, compared to analysts’ expectations of $64.73 million. During the same period in the previous year, the company earned ($4.00) earnings per share. Equities research analysts anticipate that Agenus Inc. will post -10.87 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on AGEN. Jefferies Financial Group restated a “hold” rating and issued a $7.00 target price (up from $3.00) on shares of Agenus in a research note on Friday, July 19th. HC Wainwright downgraded shares of Agenus from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $40.00 to $9.00 in a research note on Thursday, July 18th. Robert W. Baird lowered shares of Agenus from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $35.00 to $8.00 in a research report on Friday, July 19th. Baird R W lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a report on Friday, July 19th. Finally, StockNews.com downgraded Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Agenus has a consensus rating of “Hold” and an average target price of $10.50.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.